Abstract:Cardiac fibrosis is a major and complex pathophysiological process that ultimately culminates in cardiac dysfunction and heart failure. This phenomenon includes not only the replacement of the damaged tissue by a fibrotic scar produced by activated fibroblasts/myofibroblasts but also a spatiotemporal alteration of the structural, biochemical, and biomechanical parameters in the ventricular wall, eliciting a reactive remodeling process. Though mechanical stress, post-infarct homeostatic imbalances, and neurohormonal activation are classically attributed to cardiac fibrosis, emerging evidence that supports the roles of immune system modulation, inflammation, and metabolic dysregulation in the initiation and progression of cardiac fibrogenesis has been reported. Adaptive changes, immune cell phenoconversions, and metabolic shifts in the cardiac nonmyocyte population provide initial protection, but persistent altered metabolic demand eventually contributes to adverse remodeling of the heart. Altered energy metabolism, mitochondrial dysfunction, various immune cells, immune mediators, and cross-talks between the immune cells and cardiomyocytes play crucial roles in orchestrating the transdifferentiation of fibroblasts and ensuing fibrotic remodeling of the heart. Manipulation of the metabolic plasticity, fibroblast–myofibroblast transition, and modulation of the immune response may hold promise for favorably modulating the fibrotic response following different cardiovascular pathological processes. Although the immunologic and metabolic perspectives of fibrosis in the heart are being reported in the literature, they lack a comprehensive sketch bridging these two arenas and illustrating the synchrony between them. This review aims to provide a comprehensive overview of the intricate relationship between different cardiac immune cells and metabolic pathways as well as summarizes the current understanding of the involvement of immune–metabolic pathways in cardiac fibrosis and attempts to identify some of the previously unaddressed questions that require further investigation. Moreover, the potential therapeutic strategies and emerging pharmacological interventions, including immune and metabolic modulators, that show promise in preventing or attenuating cardiac fibrosis and restoring cardiac function will be discussed.

Cardiac and perivascular myofibroblasts, matrifibrocytes, and immune fibrocytes in hypertension; commonalities and differences with myocardial infarction and other cardiovascular diseases

Emerging Roles of Fibroblasts in Cardiovascular Calcification

Fibroblasts under pressure: cardiac fibroblast responses to hypertension and antihypertensive therapies

Cardiac fibrosis.

Cardiac Fibrosis and Fibroblasts

Myofibroblasts and Fibrosis

Targeting immune-fibroblast cell communication in heart failure

Cardiac Fibrosis: New Insights into the Pathogenesis

Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease

Abstract 2149: Smooth Muscle-derived Resident Vascular Adventitial Progenitor Cell Contribution To Cardiac Fibrosis And Inflammation Is Dependent On KLF4

Properties and Functions of Fibroblasts and Myofibroblasts in Myocardial Infarction

The Pathogenesis of Cardiac Fibrosis: A Review of Recent Progress

Cardiac fibrogenesis: an immuno-metabolic perspective

MicroRNAs Involved in the Regulation of Postischemic Cardiac Fibrosis

Fibroblasts in Pulmonary Hypertension: Roles and Molecular Mechanisms

Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair

Single-cell transcriptomics reveal distinctive patterns of fibroblast activation in heart failure with preserved ejection fraction

Cardiac Fibrosis: Key Role of Integrins in Cardiac Homeostasis and Remodeling

Targeting Interactions between Fibroblasts and Macrophages to Treat Cardiac Fibrosis

Different Roles of Resident and Non-resident Macrophages in Cardiac Fibrosis

Cardiac Fibroblastic Niches in Homeostasis and Inflammation